Clearbridge Investments, LLC Olink Holding Ab (Publ) Transaction History

Clearbridge Investments, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$14.29 - $25.95 $16.4 Million - $29.7 Million	-1,146,429 Reduced 76.72%	347,892 $8.75 Million
Q3 2023 Nov 13, 2023	SELL	$14.45 - $20.34 $64,548 - $90,858	-4,467 Reduced 0.3%	1,494,321 $22 Million
Q2 2023 Aug 11, 2023	BUY	$17.13 - $23.74 $77,616 - $107,565	4,531 Added 0.3%	1,498,788 $28.1 Million
Q1 2023 May 12, 2023	BUY	$19.34 - $24.11 $394,671 - $492,012	20,407 Added 1.38%	1,494,257 $33.7 Million
Q4 2022 Feb 10, 2023	BUY	$12.64 - $25.52 $212,250 - $428,531	16,792 Added 1.15%	1,473,850 $37.4 Million
Q3 2022 Nov 14, 2022	BUY	$12.14 - $18.42 $82,479 - $125,145	6,794 Added 0.47%	1,457,058 $17.7 Million
Q2 2022 Aug 11, 2022	BUY	$8.95 - $19.24 $20,003 - $43,001	2,235 Added 0.15%	1,450,264 $22 Million
Q1 2022 May 13, 2022	BUY	$11.33 - $19.3 $132,051 - $224,941	11,655 Added 0.81%	1,448,029 $25.6 Million
Q4 2021 Feb 11, 2022	BUY	$18.0 - $34.82 $5.79 Million - $11.2 Million	321,697 Added 28.86%	1,436,374 $26.1 Million
Q3 2021 Nov 12, 2021	BUY	$23.42 - $37.93 $8.19 Million - $13.3 Million	349,876 Added 45.75%	1,114,677 $27 Million
Q2 2021 Aug 13, 2021	BUY	$26.65 - $39.47 $20.4 Million - $30.2 Million	764,801 New	764,801 $26.3 Million

37M

34.9K

110K

Ticker OLK
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 119,098,000
Description
Olink Holding AB (publ) provides various products and services for the academic, government, biopharmaceutical, biotechnology, and other institutions that focuses on life science research. Its products include Olink Explore for cardiovascular and metabolic, oncology, neurology, or inflammation diseases; Olink Target product line; and Olink Focus...

Get notified when there are updates to the investment portfolio of Clearbridge Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Clearbridge Investments, LLC with notifications on news.